SEP 1 2 2007 **COMPLETE IF KNOWN** Substitute for form 1449A/PTO INFORMATION DISCESSURE Application Number 10/558,931 STATEMENT BY APPLICATE Filing Date November 30, 2005 First Named Inventor Scott D. Edmondson, et al. 1626 Group Art Unit (use as many sheets as necessary) SHAMEEM G. **Examiner Name** 1 of 4 Sheet 21431P Attorney Docket Number

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/GS/	1	US 4,386,090 \		Moinet, et al.	05/31/1983
	2	US 4,698,351		Hausberg, et al.	10/06/1987
	3	US 5,939,560		Jenkins, et al.	08/17/1999
	4	US 6,011,155		Villhauer	01/04/2000
	5	US 6,166,063		Villhauer	12/26/2000
	6	US 6,303,661 B1		Demuth, et al.	10/16/2001
	7	US 6,432,969 B1		Villhauer	08/13/2002
\/	8	US 6,699,871 B2		Edmondson, et al.	03/02/2004
V					
					·
		·			

				FOREI	GN PATENT	DOCUMENTS	
Exam	Examiner Cite Initials* No.			Foreign Patent Documen	t Kind	Name of Patentee or Applicant	Date of Publication of
Initial			Office	Number	Code (if known)	of Cited Document	Cited Document MM-DD-YYYY
7GS	S/	1	PCT	WO 97/40832		Hans-Knoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
		2	PCT	WO 98/19998		Novartis AG	05/14/1998
		3	PCT	WO 00/34241	·	Novartis AG	06/15/2000
		4	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
		5	PCT	WO 01/42262 A2		AKZO Nobel N. V.	06/14/2001
		6	PCT	WO 01/96295 A2		Novartis AG	12/20/2001
		7	PCT	WO 02/02560 A2		Novo Nordisk A/S	01/10/2002
		8	PCT	WO 02/076450 A1		Merck & Co., Inc.	10/03/2002
		9	PCT	WO 03/000180 A2		Merck & Co., Inc.	01/03/2003
W_		10	PCT	WO 03/000181 A2		Merck & Co., Inc.	01/03/2003

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

/Golam Shameem/

Date Considered

11/19/2007

Su	sbstitute for form 1449A/PTO			COMPLETE IF KNOWN			
I	NFORMATION	DIS	CLOSURE	Application Number	10/558,931		
	TO A TOTAL MEDICAL TO NA	A TO		Filing Date	November 30, 2005		
3	TATEMENT BY	AP	PLICANI	First Named Inventor	Scott D. Edmondson, et al		
				Group Art Unit			
1	(use as many sheets	as n	secessary)	Examiner Name			
Sheet	2	of	4	Attorney Docket Number	21431P		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Docur Number	nent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		· · · · · · · · · · · · · · · · · · ·					
	•						
	•						

				FOREIG	N PATENT	T DOCUMENTS	
_				Foreign Patent Document			Date of Publication of
Exam Initial	s*	Cite No.	Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
7GS	S/	11	PCT	WO 03/082817 A2		Merck & Co., Inc.	10/09/2003
		12	PCT	WO 2004/007468 A1		Merck & Co., Inc.	01/22/2004
		13	PCT	WO 2004/032836 A2		Merck & Co., Inc.	04/22/2004
		14	PCT	WO 2004/043940 A1		Merck & Co., Inc.	05/27/2004
		15	PCT	WO 2004/050022 A2		Merck & Co., Inc.	06/17/2004
		16	PCT	WO 2004/058266 A1		Merck & Co., Inc.	07/15/2004
		17	PCT	WO 2004/064778 A2		Merck & Co., Inc.	08/05/2004
		18	PCT.	WO 2004/069162 A2		Merck & Co., Inc.	08/19/2004
		19	PCT	WO 2004/110436 A1		Merck & Co., Inc.	12/23/2004
V		20	PCT	WO 2004/112701 A2		Merck & Co., Inc.	12/29/2004

Examiner Signature /Golam Shameem/ Date Considered 11/19/2007

Su	ubstitute for form 1449A/PTO				COMPLETE IF KNOWN
I	NFORMATION	DIS	CLOSURE	Application Number	10/558,931
	TATEMENT BY	' A TO	DIICANT	Filing Date	November 30, 2005
S	IAIEMENI DI	Ar	PLICANI	First Named Inventor	Scott D. Edmondson, et al.
			,	Group Art Unit	·
	(use as many sheets	as n	ecessary)	Examiner Name	
Sheet	3	of	4	Attorney Docket Number	21431P

U.S. PATENT DOCUMENTS							
Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
•							
	/ No						
	No.	Cite No. Number	Cite No. Number Kind Code (if known)	Cite No. Number Kind Code (if known) Name of Patentee or Applicant of Cited Document			

			FOREI	GN PATENT	r DOCUMENTS	
	0		Foreign Patent Documen	t		Date of Publication of
Examine Initials*	Cite No.	Office	Number .	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
/GS/	21	PCT	WO 2005/011581 A2		Merck & Co., Inc.	02/10/2005
	22	PCT	WO 2005/044195 A2		Merck & Co., Inc.	05/19/2005
	23	PCT	WO 2005/056003 A1		Graffinity Pharmaceuticals AG	06/23/2005
	24	PCT	WO 2005/056013 A1		Graffinity Pharmaceuticals AG	06/23/2005
	25	PCT	WO 2005/108382 A1		Merck & Co., Inc.	11/17/2005
	26	PCT	WO 2005/116029 A1		Merck & Co., Inc.	12/08/2005
V	27	PCT	WO 2005/123685 A1		Astrazeneca AB	12/29/2005
				٠,		

Examiner | /Golam Shameem/ | Date | Considered | 11/19/2007 |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

s	ubstitute for form 1449B/PTO		•	COMPLETE IF KNOWN			
INFORMATION DISCLOSURE				Application Number	10/558,931		
	STATEMENT BY	7 A TD	DITCANT	Filing Date	November 30, 2005		
	·	Ar	PLICANI	First Named Inventor	Scott D. Edmondson, et al.		
			,	Group Art Unit			
	(use as many sheet	s as n	iecessary)	Examiner Name			
Sheet	4	of	4	Attorney Docket Number	21431P		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/GS/	1	Augustyns, K, et al., "Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes", Expert Opin. Ther. Patent, Vol. 13, No. 4, pp 499-510, 2003
	2	Augustyns, K. et al., "Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", Expert Opin. Ther. Patents, Vol. 15, No. 10, pp 1387-1407, 2005
	3	Deacon, C. F., "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, pp 2181-2189, 2004
	4	Deacon, C. F. et al., "Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?", Expert Opin. Investig. Drugs, Vol. 13, No. 9, pp 1091-1102, 2004
	5	Drucker, D. J., "Therapeutic potential of dipeptidyl peptidase IV inhibtors for the treatment of type 2 diabetes", Expert Opin. Investig. Drugs, Vol. 12, No. 1, pp 87-100, 2003
	6	Holst, J. J., "Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors", Expert Opin. Emerg. Drugs, Vol. 9, No. 1, pp 155-166, 2004
	7	Holst, J. J. et al., "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Current Opinion in Pharmacology, Vol. 4, pp 589-596, 2004
	8	Knudsen, L. B., "Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes" J. Med. Chem., Vol. 47, pp 4128-4134, 2004
	9	Novartis AG: WO0034142 - Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus", Exp. Opin. Ther. Patents, Vol. 10, No. 12, pp 1937-1942, 2000
	10	Demuth, H. U. et al., "Type 2 diabetes - Therapy with dipeptidyl peptidase IV inhibitors", Biochimica et Biophysica Acta, Vol. 1751, pp 33-44, 2005
	11	Vahl, T. P. et al., "Gut peptides in the treatment of diabetes mellitus", Expert Opin. Investig. Drugs, Vol. 13, No. 3, pp 177-188, 2004
V	1.2	Weber, A. E., "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes" J. Med. Chem, Vol. 47, pp 4135-4141, 2004
	<u> </u>	L

Examiner Signature /Golam Shameem/	Date Considered	11/19/2007

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007)